Lantheus Holdings Inc. (NASDAQ:LNTH) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
A number of other research firms have also commented on LNTH. Credit Suisse Group AG began coverage on Lantheus Holdings in a research note on Friday, September 23rd. They set a “neutral” rating and a $8.00 price objective on the stock. Jefferies Group increased their price objective on Lantheus Holdings from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, August 29th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Lantheus Holdings presently has a consensus rating of “Hold” and an average target price of $7.40.
Lantheus Holdings (NASDAQ:LNTH) traded down 1.91% during trading on Wednesday, reaching $8.23. The company’s stock had a trading volume of 278,890 shares. Lantheus Holdings has a 1-year low of $1.76 and a 1-year high of $10.10. The company’s 50-day moving average is $8.40 and its 200-day moving average is $4.40. The company has a market capitalization of $250.08 million, a P/E ratio of 9.29 and a beta of 0.45.
Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.18. The business had revenue of $78 million for the quarter, compared to analyst estimates of $72.66 million. Lantheus Holdings had a negative return on equity of 11.75% and a net margin of 9.00%. Equities analysts anticipate that Lantheus Holdings will post $0.55 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Brigade Capital Management LP acquired a new position in Lantheus Holdings during the second quarter valued at $5,219,000. Globeflex Capital L P acquired a new position in Lantheus Holdings during the second quarter valued at $1,410,000. BlackRock Institutional Trust Company N.A. increased its position in Lantheus Holdings by 4.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 202,183 shares of the company’s stock valued at $742,000 after buying an additional 7,875 shares during the period. Gabelli Funds LLC increased its position in Lantheus Holdings by 22.2% in the second quarter. Gabelli Funds LLC now owns 165,000 shares of the company’s stock valued at $606,000 after buying an additional 30,000 shares during the period. Finally, GSA Capital Partners LLP increased its position in Lantheus Holdings by 3.7% in the second quarter. GSA Capital Partners LLP now owns 154,322 shares of the company’s stock valued at $566,000 after buying an additional 5,500 shares during the period. Hedge funds and other institutional investors own 30.15% of the company’s stock.
About Lantheus Holdings
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.